Integration of Transcriptomics and Proteomics to Elucidate Inhibitory Effect and Mechanism of Antifungalmycin B from Marine Streptomyces hiroshimensis in Treating Talaromyces marneffei DOI Creative Commons

Qiqi Li,

Zhou Wang,

Cuiping Jiang

et al.

Marine Drugs, Journal Year: 2025, Volume and Issue: 23(2), P. 76 - 76

Published: Feb. 10, 2025

Talaromyces marneffei (TM) is an opportunistic pathogenic fungus that mainly infects immunocompromised patients. Currently, the global prevalence of talaromycosis caused by TM increasing, leading to increased demand for anti-TM drugs. In our previous study, a novel 28-membered macrolide compound, antifungalmycin B (ANB), was isolated from Streptomyces hiroshimensis GXIMD 06359, exhibiting significant antifungal properties. However, its in vivo mechanisms and direct effects warrant further investigation. this we employed mouse model conjunction with transcriptomic proteomic approaches explore activity ANB against T. marneffei. infected infection, significantly reduced fungal burdens liver, spleen, lungs, kidneys. Additionally, it markedly decreased levels reactive oxygen species (ROS) cytokines, including interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α. Proteomic studies, complemented parallel reaction monitoring (PRM) analysis, revealed effectively disrupted acid biosynthesis cellular energy metabolism, thereby impairing mitochondrial functions These were exerted through multiple pathways. findings highlight potential as versatile inhibitor polyene macrolide-resistant fungi, offering promising therapeutic avenue treatment talaromycosis.

Language: Английский

COVID-19 and antimicrobial resistance: A cross-study DOI Open Access

Sidra Ghazali Rizvi,

Shaikh Ziauddin Ahammad

The Science of The Total Environment, Journal Year: 2021, Volume and Issue: 807, P. 150873 - 150873

Published: Oct. 9, 2021

Language: Английский

Citations

124
COVID-19–associated mucormycosis: Evidence-based critical review of an emerging infection burden during the pandemic’s second wave in India DOI Creative Commons
Jesil Mathew Aranjani, Atulya Manuel, Habeeb Ibrahim Abdul Razack

et al.

PLoS neglected tropical diseases, Journal Year: 2021, Volume and Issue: 15(11), P. e0009921 - e0009921

Published: Nov. 18, 2021

Coronavirus Disease 2019 (COVID-19), during the second wave in early 2021, has caused devastating chaos India. As daily infection rates rise alarmingly, number of severe cases increased dramatically. The country encountered health infrastructure inadequacy and excessive demand for hospital beds, drugs, vaccines, oxygen. Adding more burden to such a challenging situation, mucormycosis, an invasive fungal infection, seen sudden surge patients with COVID-19. rhino-orbital-cerebral form is most common type observed. In particular, approximately three-fourths them had diabetes as predisposing comorbidity received corticosteroids treat Possible mechanisms may involve immune inflammatory processes. Diabetes, when coupled COVID-19–induced systemic change, tends cause decreased immunity risk secondary infections. Since comprehensive data on this fatal opportunistic are evolving against backdrop major pandemic, prevention strategies primarily managing comorbid conditions high-risk groups. recommended treatment included surgical debridement antifungal therapy using Amphotericin B selected azoles. Several India-centric clinical guidelines have emerged rightly diagnose characterise presentation, understand pathogenesis involved, track disease course. Code Mucor one, which proposes simple but reliable staging system form. A recently been proposed, dedicated registry started. critical review, we extensively analyse recent evidence guidance COVID-19–associated mucormycosis

Language: Английский

Citations

107
Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors DOI Creative Commons
Levente Zsichla, Viktor Müller

Viruses, Journal Year: 2023, Volume and Issue: 15(1), P. 175 - 175

Published: Jan. 7, 2023

The clinical course and outcome of COVID-19 are highly variable, ranging from asymptomatic infections to severe disease death. Understanding the risk factors is relevant both in setting at epidemiological level. Here, we provide an overview host, viral environmental that have been shown or (in some cases) hypothesized be associated with outcomes. considered detail include age frailty, genetic polymorphisms, biological sex (and pregnancy), co- superinfections, non-communicable comorbidities, immunological history, microbiota, lifestyle patient; variation infecting dose; socioeconomic factors; air pollution. For each category, compile (sometimes conflicting) evidence for association factor outcomes (including strength effect) outline possible action mechanisms. We also discuss complex interactions between various factors.

Language: Английский

Citations

71
The WHO fungal priority pathogens list: a crucial reappraisal to review the prioritisation DOI Creative Commons
Giacomo Casalini, Andrea Giacomelli, Spinello Antinori

et al.

The Lancet Microbe, Journal Year: 2024, Volume and Issue: 5(7), P. 717 - 724

Published: April 9, 2024

In October, 2022, WHO published the first fungal priority pathogen list, which categorised 19 entities into three groups (critical, high, and medium), for prioritisation of research efforts. The final ranking was determined via multiple criteria decision analysis, considering both development needs perceived public health importance. this Personal View, we discuss positioning pathogens, namely, Mucorales, Candida spp, Histoplasma Coccidioides Paracoccidioides Fusarium eumycetoma causative agents, Talaromyces marneffei, Pneumocystis jirovecii, while expressing concerns about potential disparities between list actual disease burden associated with these pathogens. Finally, propose a revised that also considers regional in diseases.

Language: Английский

Citations

38
Invasive Fungal Infections Complicating COVID-19: A Narrative Review DOI Creative Commons
Giacomo Casalini, Andrea Giacomelli,

Annalisa Ridolfo

et al.

Journal of Fungi, Journal Year: 2021, Volume and Issue: 7(11), P. 921 - 921

Published: Oct. 29, 2021

Invasive fungal infections (IFIs) can complicate the clinical course of COVID-19 and are associated with a significant increase in mortality, especially critically ill patients admitted to an intensive care unit (ICU). This narrative review concerns 4099 cases IFIs 58,784 involved 168 studies. COVID-19-associated invasive pulmonary aspergillosis (CAPA) is diagnostic challenge because its non-specific clinical/imaging features fact that proposed clinically algorithms do not really apply patients. Forty-seven observational studies 41 case reports have described total 478 CAPA were mainly diagnosed on basis cultured respiratory specimens and/or biomarkers/molecular biology, usually without histopathological confirmation. Candidemia widely secondary infection undergoing prolonged hospitalisation, 401 indicate high crude mortality rates 56.1% 74.8%, respectively. often characterised by presence known risk factors for candidemia such as in-dwelling vascular catheters, mechanical ventilation, broad-spectrum antibiotics. We also describe 3185 mucormycosis (including 1549 rhino-orbital (48.6%)), which main factor history poorly controlled diabetes mellitus (>76%). Its diagnosis involves examination tissue biopsies, treatment requires anti-fungal therapy combined aggressive surgical resection/debridement, but again high: 50.8% 16% The other severely immunocompromised show SARS-CoV-2 capable stunning host immune system: 20 Pneumocystis jirovecii pneumonia, 5 cryptococcosis, 4 histoplasmosis, 1 coccidioides infection, due Fusarium spp., Scedosporium.

Language: Английский

Citations

83
Pathogenesis of Respiratory Viral and Fungal Coinfections DOI
Fabián Salazar, Elaine Bignell, Gordon D. Brown

et al.

Clinical Microbiology Reviews, Journal Year: 2021, Volume and Issue: 35(1)

Published: Nov. 17, 2021

Individuals suffering from severe viral respiratory tract infections have recently emerged as "at risk" groups for developing invasive fungal infections. Influenza virus is one of the most common causes acute lower worldwide. Fungal complicating influenza pneumonia are associated with increased disease severity and mortality, pulmonary aspergillosis being manifestation. Strikingly, similar observations been made during current coronavirus 2019 (COVID-19) pandemic. The copathogenesis coinfections complex involves a dynamic interplay between host immune defenses virulence microbes involved that often results in failure to return homeostasis. In this review, we discuss main mechanisms underlying susceptibility following A comprehensive understanding these interactions will aid development therapeutic modalities against newly identified targets prevent treat emerging coinfections.

Language: Английский

Citations

61
Increased Deaths From Fungal Infections During the Coronavirus Disease 2019 Pandemic—National Vital Statistics System, United States, January 2020–December 2021 DOI Open Access
Jeremy A.W. Gold,

Farida B. Ahmad,

Jodi A. Cisewski

et al.

Clinical Infectious Diseases, Journal Year: 2022, Volume and Issue: 76(3), P. e255 - e262

Published: June 19, 2022

Coronavirus disease 2019 (COVID-19)-associated fungal infections cause severe illness, but comprehensive data on burden are lacking. We analyzed US National Vital Statistics System (NVSS) to characterize burden, temporal trends, and demographic characteristics of persons dying during the COVID-19 pandemic.Using NVSS's January 2018-December 2021 Multiple Cause Death Database, we examined numbers age-adjusted rates (per 100 000 population) deaths due infection by pathogen, association, characteristics, year.Numbers increased from (n = 4833; rate, 1.2 [95% confidence interval, 1.2-1.3]) 7199; 1.8 [1.8-1.8] per 000); 13 121 such 2020-2021, 2868 (21.9%) were associated. Compared with non-COVID-19-associated 10 253), COVID-19-associated more frequently involved Candida 776 [27.1%] vs n 2432 [23.7%], respectively) Aspergillus 668 [23.3%] 1486 [14.5%]) less other specific pathogens. Rates death generally highest in nonwhite non-Asian populations. approximately 2 times higher Pacific census division compared most divisions.Deaths 2020-2021 previous years, primarily driven deaths, particularly those involving Candida. Our findings may inform efforts prevent, identify, treat patients COVID-19, especially certain racial/ethnic groups geographic areas.

Language: Английский

Citations

49
The Impact of Coronavirus Disease 2019 on Viral, Bacterial, and Fungal Respiratory Infections DOI Open Access
Ashley Losier,

Gayatri Gupta,

Mario Caldararo

et al.

Clinics in Chest Medicine, Journal Year: 2023, Volume and Issue: 44(2), P. 407 - 423

Published: Feb. 26, 2023

Language: Английский

Citations

25
Molecular architecture of chitin and chitosan-dominated cell walls in zygomycetous fungal pathogens by solid-state NMR DOI Creative Commons

Qinghui Cheng,

Malitha C. Dickwella Widanage, Jayasubba Reddy Yarava

et al.

Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)

Published: Sept. 27, 2024

Language: Английский

Citations

9
Moesziomyces aphidis Bloodstream Infection in Oncologic Patient: First Report in Poland DOI Creative Commons
Beata Sulik‐Tyszka, Jolanta Małyszko,

Agnieszka Pęczuła

et al.

Journal of Fungi, Journal Year: 2025, Volume and Issue: 11(2), P. 95 - 95

Published: Jan. 24, 2025

Moesziomyces spp. (Pseudozyma) is a genus recognized as new opportunistic human pathogen, causing systemic infections including premature neonates and adult patients. These fungi’s natural resistance to caspofungin enables them spread through vascular catheter colonization, making etiological agent associated with fungal bloodstream (FBIs) significant contributor high mortality rates. In this report, we present case of fungemia caused by aphidis species in patient medical history that revealed pancreatic cancer infiltrating the duodenum bile ducts. During hospitalization, M. was cultured twice from peripheral blood samples on Sabouraud agar. The strain sensitive amphotericin B voriconazole. vitro susceptibility testing fluconazole, caspofungin, anidulafungin, micafungin. Antifungal therapy voriconazole resulted resolution clinical symptoms infection. Related fungemia, reviewed total three cases Europe published PubMed database between 2003 2024. To best our knowledge, first FBI Poland fourth an Europe.

Language: Английский

Citations

1